Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.
BACKGROUND:Follicular lymphoma is the second most common non-Hodgkin lymphoma in the United States and Europe. However, most of the prospective randomized studies have very little follow-up compared to the long natural history of the disease. The primary aim of this study was to investigate the long...
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5426713?pdf=render |
id |
doaj-6e236207a74245ef906d5faa5f1d0dde |
---|---|
record_format |
Article |
spelling |
doaj-6e236207a74245ef906d5faa5f1d0dde2020-11-25T01:59:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01125e017720410.1371/journal.pone.0177204Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.Mariano ProvencioPilar SabínJose Gomez-CodinaMaria TorrenteVirginia CalvoMarta LlanosJosep GumáCristina QueroAna BlascoMiguel Angel CruzDavid AguiarFrancisco García-ArroyoJavier LaverniaNatividad MartinezManuel MoralesAlvaro Saez-CusiDelvys RodriguezLuis de la CruzJose Javier SanchezAntonio RuedaGOTEL (Spanish Lymphoma Oncology Group)BACKGROUND:Follicular lymphoma is the second most common non-Hodgkin lymphoma in the United States and Europe. However, most of the prospective randomized studies have very little follow-up compared to the long natural history of the disease. The primary aim of this study was to investigate the long-term survival of our series of patients with follicular lymphoma. PATIENTS AND METHODS:A total of 1074 patients with newly diagnosed FL were enrolled. Patients diagnosed were prospectively enrolled from 1980 to 2013. RESULTS:Median follow-up was 54.9 months and median overall survival is over 20 years in our series. We analyzed the patients who are still alive beyond 10 years from diagnosis in order to fully assess the prognostic factors that condition this group. Out of 166 patients who are still alive after more than 10 years of follow-up, 118 of them (73%) are free of evident clinical disease. Variables significantly associated with survival at 10 years were stage < II (p <0.03), age < 60 years (p <0.0001), low FLIPI (p <0.002), normal β2 microglobulin (p <0.005), no B symptoms upon diagnosis (p <0.02), Performance Status 0-1 (p <0.03) and treatment with anthracyclines and rituximab (p <0.001), or rituximab (p <0.0001). CONCLUSIONS:A longer follow-up and a large series demonstrated a substantial population of patients with follicular lymphoma free of disease for more than 10 years.http://europepmc.org/articles/PMC5426713?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mariano Provencio Pilar Sabín Jose Gomez-Codina Maria Torrente Virginia Calvo Marta Llanos Josep Gumá Cristina Quero Ana Blasco Miguel Angel Cruz David Aguiar Francisco García-Arroyo Javier Lavernia Natividad Martinez Manuel Morales Alvaro Saez-Cusi Delvys Rodriguez Luis de la Cruz Jose Javier Sanchez Antonio Rueda GOTEL (Spanish Lymphoma Oncology Group) |
spellingShingle |
Mariano Provencio Pilar Sabín Jose Gomez-Codina Maria Torrente Virginia Calvo Marta Llanos Josep Gumá Cristina Quero Ana Blasco Miguel Angel Cruz David Aguiar Francisco García-Arroyo Javier Lavernia Natividad Martinez Manuel Morales Alvaro Saez-Cusi Delvys Rodriguez Luis de la Cruz Jose Javier Sanchez Antonio Rueda GOTEL (Spanish Lymphoma Oncology Group) Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry. PLoS ONE |
author_facet |
Mariano Provencio Pilar Sabín Jose Gomez-Codina Maria Torrente Virginia Calvo Marta Llanos Josep Gumá Cristina Quero Ana Blasco Miguel Angel Cruz David Aguiar Francisco García-Arroyo Javier Lavernia Natividad Martinez Manuel Morales Alvaro Saez-Cusi Delvys Rodriguez Luis de la Cruz Jose Javier Sanchez Antonio Rueda GOTEL (Spanish Lymphoma Oncology Group) |
author_sort |
Mariano Provencio |
title |
Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry. |
title_short |
Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry. |
title_full |
Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry. |
title_fullStr |
Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry. |
title_full_unstemmed |
Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry. |
title_sort |
impact of treatment in long-term survival patients with follicular lymphoma: a spanish lymphoma oncology group registry. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2017-01-01 |
description |
BACKGROUND:Follicular lymphoma is the second most common non-Hodgkin lymphoma in the United States and Europe. However, most of the prospective randomized studies have very little follow-up compared to the long natural history of the disease. The primary aim of this study was to investigate the long-term survival of our series of patients with follicular lymphoma. PATIENTS AND METHODS:A total of 1074 patients with newly diagnosed FL were enrolled. Patients diagnosed were prospectively enrolled from 1980 to 2013. RESULTS:Median follow-up was 54.9 months and median overall survival is over 20 years in our series. We analyzed the patients who are still alive beyond 10 years from diagnosis in order to fully assess the prognostic factors that condition this group. Out of 166 patients who are still alive after more than 10 years of follow-up, 118 of them (73%) are free of evident clinical disease. Variables significantly associated with survival at 10 years were stage < II (p <0.03), age < 60 years (p <0.0001), low FLIPI (p <0.002), normal β2 microglobulin (p <0.005), no B symptoms upon diagnosis (p <0.02), Performance Status 0-1 (p <0.03) and treatment with anthracyclines and rituximab (p <0.001), or rituximab (p <0.0001). CONCLUSIONS:A longer follow-up and a large series demonstrated a substantial population of patients with follicular lymphoma free of disease for more than 10 years. |
url |
http://europepmc.org/articles/PMC5426713?pdf=render |
work_keys_str_mv |
AT marianoprovencio impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT pilarsabin impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT josegomezcodina impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT mariatorrente impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT virginiacalvo impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT martallanos impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT josepguma impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT cristinaquero impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT anablasco impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT miguelangelcruz impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT davidaguiar impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT franciscogarciaarroyo impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT javierlavernia impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT natividadmartinez impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT manuelmorales impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT alvarosaezcusi impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT delvysrodriguez impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT luisdelacruz impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT josejaviersanchez impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT antoniorueda impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry AT gotelspanishlymphomaoncologygroup impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry |
_version_ |
1724963942994804736 |